Tudor Investment Corp
ALXN

Tudor Investment Corp’s Alexion Pharmaceuticals ALXN Stock Holding History

Tudor Investment Corp’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-907,855
Closed -$167M – 2980
2021
Q2 		$167M Buy
907,855
+380,114
+72% +$65.2M 3.15% 1
2021
Q1 		$80.7M Buy
527,741
+194,364
+58% +$30.1M 1.62% 3
2020
Q4 		$52.1M Buy
333,377
+261,377
+363% +$33.6M 1.47% 9
2020
Q3 		$8.24M Buy
72,000
+52,405
+267% +$5.65M 0.36% 37
2020
Q2 		$2.2M Sell
19,595
-4,502
-19% -$478K 0.11% 222
2020
Q1 		$2.16M Sell
24,097
-42,873
-64% -$4.21M 0.19% 85
2019
Q4 		$7.24M Sell
66,970
-22,101
-25% -$2.36M 0.32% 50
2019
Q3 		$8.72M Buy
89,071
+27,817
+45% +$3.14M 0.3% 52
2019
Q2 		$8.02M Buy
61,254
+43,599
+247% +$5.62M 0.23% 42
2019
Q1 		$2.39M Sell
17,655
-15,937
-47% -$1.98M 0.1% 230
2018
Q4 		$3.27M Buy
33,592
+26,725
+389% +$3.16M 0.06% 103
2018
Q3 		$955K Sell
6,867
-30,876
-82% -$3.87M 0.02% 483
2018
Q2 		$4.69M Buy
37,743
+17,541
+87% +$2.05M 0.16% 86
2018
Q1 		$2.25M Buy
20,202
+17,938
+792% +$2.14M 0.07% 139
2017
Q4 		$271K Sell
2,264
-11,161
-83% -$1.36M 0.01% 857
2017
Q3 		$1.88M Buy
13,425
+6,218
+86% +$845K 0.05% 226
2017
Q2 		$877K Buy
7,207
+170
+2% +$19.8K 0.03% 381
2017
Q1 		$853K Buy
7,037
+5,337
+314% +$688K 0.03% 453
2016
Q4 		$208K Sell
1,700
-151,811
-99% -$18.6M 0.01% 1209
2016
Q3 		$18.8M Buy
153,511
+140,182
+1,052% +$18M 0.44% 41
2016
Q2 		$1.56M Buy
+13,329
New +$1.89M 0.03% 285
2015
Q3 		– Sell
-1,501
Closed -$271K – 1817
2015
Q2 		$271K Sell
1,501
-1,730
-54% -$299K 0.01% 1164
2015
Q1 		$560K Buy
3,231
+1,744
+117% +$316K 0.02% 674
2014
Q4 		$275K Sell
1,487
-1,633
-52% -$303K 0.01% 1092
2014
Q3 		$517K Buy
3,120
+1,794
+135% +$295K 0.02% 652
2014
Q2 		$207K Sell
1,326
-4,399
-77% -$695K 0.01% 1028
2014
Q1 		$871K Buy
+5,725
New +$910K 0.04% 248
2013
Q3 		– Sell
-3,800
Closed -$351K – 1000
2013
Q2 		$351K Buy
+3,800
New +$366K 0.03% 482

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tudor Investment Corp's ALXN Position: Q3 2021 in Review

Tudor Investment Corp sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 907,855 shares — an estimated $167M sold.

Tudor Investment Corp first reported a position in ALXN in Q2 2013 and held it in 28 quarters. The position peaked at $167M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Tudor Investment Corp reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tudor Investment Corp sold 907,855 Alexion Pharmaceuticals shares in Q3 2021, an estimated $167M.
  • Tudor Investment Corp first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • Tudor Investment Corp's Alexion Pharmaceuticals position peaked at $167M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.